CTNM 8-K 2026-11-03

Contineum Therapeutics, Inc. (CTNM) 8-K dated 2026-11-03 — accession 0001628280-26-069493.

Contineum Therapeutics, Inc. (CTNM) is a biotechnology company listed on US.

Contineum Therapeutics, Inc. filed a 8-K on 2026-11-03. Accession 0001628280-26-069493.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported CTNM revenue for 2024-12-31 was $0. Net income was -$42.3M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. CTNM currently screens at market cap $429.6M.

Not investment advice. The CTNM SEC hub lists recent forms. The stock page is the research view.